The new COO at Hybrigenics has made a number of jumps in her career. Starting out in research, she headed to development and later moved again when an offer came along and piqued her curiosity about working on the business side. Now, she’s making the shift from big pharma to a small proteomics company. “It is indeed a major new challenge in my career,” says Anne-Fabienne Weitsch.
Formerly senior director of licensing and business development at Johnson & Johnson, Weitsch got first-hand experience navigating the biotech world (and airports: “I was living in Belgium and spending 40 percent of my time in the US,” she says). After eight years at J&J and previous time in R&D at her native Switzerland’s CIBA, she decided she was ready to move to the smaller realm of proteomics and functional proteomics at Paris-based Hybrigenics.
Since she’s already well-versed in the field, “the real learning curve will be the business operations of the biotech company,” she says. “My role will be very operational, more turned toward internal [issues].” That means less traveling, but hey, it’s Paris.
— Meredith Salisbury